Effect of Statin Intensity on the Risk of Epilepsy After Ischaemic Stroke: Real-World Evidence from Population-Based Health Claims.

abstract：:The almost ubiquitous sleep disturbances in patients with depression commonly, but not always, subside with the remission of depression. Evidence linking insomnia with the risk of relapses in recurrent depression, as well as suicide, makes optimization of the treatment of insomnia associated with depression a priority...

journal_title：CNS drugs

authors： Jindal RD

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To assess the relationship between the sustained pain free (SPF) and adverse event (AE) rates associated with six oral serotonin 5-HT(1B/1D) receptor agonists (triptans) used for the treatment of acute migraine, employing data from a previous meta-analysis (that included almotriptan, eletriptan, naratriptan, ...

journal_title：CNS drugs

authors： Dodick DW,Sandrini G,Williams P

更新日期：2007-01-01 00:00:00

abstract：:Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...

journal_title：CNS drugs

authors： Ebbert JO,Fagerstrom K

更新日期：2012-01-01 00:00:00

abstract：:Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...

journal_title：CNS drugs

authors： Chan A,de Seze J,Comabella M

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. OBJECTIVES:To identify variables that predict clozapine use after a first episode of schizophrenia (FES). METHODS:Patients with FES and ≤15 days of lifetime antipsychotic treatment were followed up...

journal_title：CNS drugs

authors： Üçok A,Çıkrıkçılı U,Ergül C,Tabak Ö,Salaj A,Karabulut S,Correll CU

更新日期：2016-10-01 00:00:00

abstract：SYNOPSIS:Mirtazapine is a tetracyclic antidepressant with a novel mechanism of action; it increases noradrenergic and serotonergic neurotransmission via blockade of central α2-adrenergic auto- and heteroreceptors. The increased release of serotonin (5-hydroxytryptamine; 5-HT) stimulates serotonin 5-HT1 receptors becaus...

journal_title：CNS drugs

authors： Davis R,Wilde MI

更新日期：1996-05-01 00:00:00

abstract：:Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...

journal_title：CNS drugs

authors： Alda M

更新日期：2019-08-01 00:00:00

abstract：UNLABELLED:Tianeptine is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine; 5-HT) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites. Like the selective serotonin reuptake inhibitors (SSRIs) and...

journal_title：CNS drugs

authors： Wagstaff AJ,Ormrod D,Spencer CM

更新日期：2001-01-01 00:00:00

abstract：:Existing drug delivery methods have not led to a significant increase in survival for patients with malignant primary brain tumors. While the combination of conventional therapies consisting of surgery, radiotherapy, and chemotherapy has improved survival for some types of brain tumors (e.g., WNT medulloblastoma), oth...

journal_title：CNS drugs

authors： Haumann R,Videira JC,Kaspers GJL,van Vuurden DG,Hulleman E

更新日期：2020-11-01 00:00:00

abstract：:NEDA was evaluated as the proportion of patients free of relapses, 3-month confirmed disability progression, and free of new or newly enlarging T2 lesion and Gadolinium enhancing lesions. ...

journal_title：CNS drugs

authors： Papadopoulos D,Mitsikostas DD

更新日期：2019-01-01 00:00:00

abstract：:Statins, or 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, such as lovastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin and pitavastatin, are cholesterol-lowering drugs used in clinical practice to prevent coronary heart disease. These drugs are generally well tolerated and have ...

journal_title：CNS drugs

authors： Tuccori M,Montagnani S,Mantarro S,Capogrosso-Sansone A,Ruggiero E,Saporiti A,Antonioli L,Fornai M,Blandizzi C

更新日期：2014-03-01 00:00:00

abstract：:L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...

journal_title：CNS drugs

authors： Schaeffer E,Pilotto A,Berg D

更新日期：2014-12-01 00:00:00

abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...

journal_title：CNS drugs

authors： Keating GM

更新日期：2013-06-01 00:00:00

abstract：:Clinically relevant movement disorders are identified in 3% of patients with HIV infection seen at tertiary referral centres. In the same setting, prospective follow-up shows that 50% of patients with AIDS develop tremor, parkinsonism or other extrapyramidal features. Hemiballism-hemichorea and tremor are the most com...

journal_title：CNS drugs

authors： Cardoso F

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...

journal_title：CNS drugs

authors： Elmer LW,Juncos JL,Singer C,Truong DD,Criswell SR,Parashos S,Felt L,Johnson R,Patni R

更新日期：2018-04-01 00:00:00

abstract：:Diclofenac potassium powder for oral solution (Voltfast(®), Catafast(®), Cambia(®); hereafter referred to as diclofenac potassium powder) is a non-steroidal anti-inflammatory drug (NSAID), and is indicated for the acute treatment of migraine. This article reviews the pharmacological properties of diclofenac potassium ...

journal_title：CNS drugs

authors： Garnock-Jones KP

更新日期：2014-08-01 00:00:00

abstract：:Naltrexone is a μ-opioid receptor antagonist that blocks the euphoric effects of heroin and prescription opioids. In order to improve treatment adherence, a once-monthly, intramuscular, extended-release formulation of naltrexone (XR-NTX) [VIVITROL(®)] has been developed, and approved in the USA and Russia for the prev...

journal_title：CNS drugs

authors： Syed YY,Keating GM

更新日期：2013-10-01 00:00:00

abstract：:Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biol...

journal_title：CNS drugs

authors： Brambilla F

更新日期：2001-01-01 00:00:00

abstract：:Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...

journal_title：CNS drugs

authors： Carter NJ,McCormack PL

更新日期：2009-01-01 00:00:00

abstract：:The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical ...

journal_title：CNS drugs

authors： Beers R,Camporesi E

更新日期：2004-01-01 00:00:00

abstract：:Sodium channel blockers have been the mainstay of the pharmacological management of focal and generalised tonic-clonic seizures for more than 70 years. The focus of this paper will be on phenytoin, carbamazepine, lamotrigine, oxcarbazepine, rufinamide, lacosamide and eslicarbazepine acetate. All these antiepileptic dr...

journal_title：CNS drugs

authors： Brodie MJ

更新日期：2017-07-01 00:00:00

abstract：:Disability, characterised by the loss of ability to perform activities of daily living (ADL), is a defining feature of dementia that results in growing caregiver burden and the eventual need for alternative care or nursing home placement. Functional decline in patients with dementia can also result from causes other t...

journal_title：CNS drugs

authors： Desai AK,Grossberg GT,Sheth DN

更新日期：2004-01-01 00:00:00

abstract：:At the beginning of the AIDS pandemic, affective disorders (such as depressed mood) were seen in a considerable number of HIV-1-infected individuals. These disorders were a result of the poor physical condition of the patients, brain involvement by the virus (e.g. encephalopathy) or a reaction to disadvantageous livin...

journal_title：CNS drugs

authors： Arendt G

更新日期：2006-01-01 00:00:00

abstract：:Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...

journal_title：CNS drugs

authors： Lee YJ

更新日期：2004-01-01 00:00:00

abstract：:Given the high heritability of the disorder, attention-deficit hyperactivity disorder (ADHD) is common among parents of children with ADHD. Parental ADHD is associated with maladaptive parenting, negative parent-child interaction patterns and a diminished response to behavioural parent training. We describe our previo...

journal_title：CNS drugs

authors： Chronis-Tuscano A,Stein MA

更新日期：2012-09-01 00:00:00

abstract：:Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...

journal_title：CNS drugs

authors： Scott LJ

更新日期：2011-08-01 00:00:00

abstract：:Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves a clinical course characterized by a progressive accumulation of neurological disability, independent of relapses, following an initial relapsing-remitting (RR) phase. Our incomplete understanding of the pathological mechanisms u...

journal_title：CNS drugs

authors： Plantone D,De Angelis F,Doshi A,Chataway J

更新日期：2016-06-01 00:00:00

abstract：PURPOSE:To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. METHODS:Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist circumference, systolic and diasto...

journal_title：CNS drugs

authors： Verrotti A,Parisi P,Agostinelli S,Loiacono G,Marra F,Coppola G,Pisani LR,Gorgone G,Striano P,Pisani F,Belcastro V

更新日期：2015-02-01 00:00:00

abstract：:Attention-deficit/hyperactivity disorder, or ADHD, is the most frequently occurring neurobiological disorder in childhood and is defined by symptoms of inattention and/or hyperactivity and impulsivity that are excessive when compared with other individuals at the same developmental level. ADHD can be successfully trea...

journal_title：CNS drugs

authors： Childress AC,Sallee FR

更新日期：2014-02-01 00:00:00

abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...

journal_title：CNS drugs

authors： Sikirica V,Findling RL,Signorovitch J,Erder MH,Dammerman R,Hodgkins P,Lu M,Xie J,Wu EQ

更新日期：2013-11-01 00:00:00